Bupivacaine ranks as the most potent and efficient drug among class I local anesthetics, but its high potential for toxic reactions severely limits its clinical use. Although bupivacaine-induced toxicity is mainly caused by substantial blockade of voltage-gated sodium channels (VGSCs), how these hydrophobic molecules interact with the receptor sites to which they bind remains unclear. Na v 1.5 is the dominant isoform of VGSCs expressed in cardiac myocytes, and its dysfunction may be the cause of bupivacainetriggered arrhythmia. Here, we investigated the effect of bupivacaine on Na v 1.5 within the clinical concentration range. The electrophysiological measurements on Na v 1.5 expressed in Xenopus oocytes showed that bupivacaine induced a voltageand concentration-dependent blockade on the peak of I Na and the half-maximal inhibitory dose was 4.51 μmol/L. Consistent with other local anesthetics, bupivacaine also induced a use-dependent blockade on Na v 1.5 currents. The underlying mechanisms of this blockade may contribute to the fact that bupivacaine not only dose-dependently affected the gating kinetics of Na v 1.5 but also accelerated the development of its open-state slow inactivation. These results extend our knowledge of the action of bupivacaine on cardiac sodium channels, and therefore contribute to the safer and more efficient clinical use of bupivacaine.
INTRODUCTION
Bupivacaine is one of the aminoamide drugs belonging to the class I local anesthetics (LAs) which include lidocaine, ropivacaine, and mepivacaine. It is generally used for infiltration and nerve block, as well as epidural and intrathecal anesthesia in clinical management. Despite its long-lasting effect when provided systemically for pain relief, patients still risk adverse drug reactions with accidental intravascular injection, inadvertent intrathecal injection, or an excessive systemic dose [1] . Systemic exposure to excessive bupivacaine mainly results in epilepsy-like syndromes due to central nervous system (CNS) excitation, and arrhythmias or cardiac arrest caused by cardiovascular toxicity [2] . Although efforts have been made to develop a controllable and safer delivery/release system for bupivacaine, a better strategy to avoid the overall toxicity is needed.
It is well-established that the main action of bupivacaine involves the use-dependent blockade of voltage-gated sodium channels (VGSCs) that are responsible for action potential initiation and axonal conduction [3] . Meanwhile, it also has a significant inhibitory effect on K + and Ca 2+ channels that contribute to the repolarization and modulatory shaping of action potentials [4, 5] . Therefore, it is reasonable to infer that membrane depolarization and increased neuronal VGSCs are transmembrane proteins consisting of an ion-conducting α-subunit and one or more auxiliary subunits [6] . Generally, the α-subunit comprises four repeated domains (DI-DIV), each c ontaining six transmembrane α-helixes (S1-S6) and a hairpin-like pore loop lining between S5 and S6 [7] . Despite the high structural similarity among VGSC isoforms, they have distinct distributions, gating properties, and functional activities [8] . To date, the bupivacaine-binding site on sodium channels has been located at the intracellular portion [9, 10] . Thereby, bupivacaine blocks Na + infl ux into neurons and prevents depolarization.
However, stereoselectivity has been reported in the bupivacaine-induced blockade of the inactivated state of Na + channels, but not on the blockade of activated (openstate) Na + channels [11] . Point-directed mutagenesis of the rat skeletal muscle Na v 1.4 channel revealed that the binding sites of bupivacaine are located in the pore-lining transmembrane segment 6 (S6) of domains 1, 3, and 4 (D1-S6, D3-S6, D4-S6), in which residues L1280 in D3-S6 and N434 in D1-S6 interact directly with bupivacaine and face each other in the ion-conducting pore [9, 10] . Even so, given that a variety of VGSC isoforms are distributed throughout human tissues, thorough investigation of how bupivacaine interacts with other Na + channels is still needed.
Na v 1.5 is responsible for the upstroke (phase 0) of the action potential in cardiac cells. Opening of the channel leads to a rapid influx of Na + (I Na ), which depolarizes the membrane potential within tenths of a millisecond [12] . Dysfunction of Na v 1.5 channels leads to various arrhythmias, such as long QT syndrome, Brugada syndrome, and cardiac conduction disease (also known as Lev-Lenegre syndrome) [13] [14] [15] . In light of this, there may be a relationship between the cardiac toxicity of bupivacaine and its use-dependent blockade of Na + channels. But it remains uncertain whether inhibition of VGSCs contributes to the systemic toxic effects of LAs, including the initial CNS excitation and pro-convulsive action [16, 17] . In this study, we investigated the pharmacological kinetics of bupivacaine on Na v 1.5 expressed in Xenopus oocytes.
MATERIALS AND METHODS

Chemicals and Solutions
Bupivacaine (Sigma-Aldrich, St. Louis, MO) was dissolved at room temperature in the bath solution ND96 (in mmol/L: NaCl 96, KCl 2, CaCl 2 1.8, MgCl 2 2, and HEPES 5, pH 7.4) at 100 mmol/L as stock solution and stored at -20°C.
Different doses of bupivacaine were prepared before use and applied to oocytes by continuous perfusion via a fast gravity-driven perfusion system. After 10 min of perfusion, step pulses were used to investigate the effect of bupivacaine on Na v 1.5 channels. The rate of perfusion with blank or test solution was adjusted to 0.1 drop per second to minimize changes in the fl ow rate.
Plasmid
The gene encoding the rat Na + channel α-subunit of Na v 1.5 in pcDNA 3.1 vector was a generous gift from Dr. Kaoru Yamaoka (Hiroshima International University, HigashiHiroshima, Hiroshima, Japan) and was sub-cloned into pSP64 Poly(A) vector (Promega, Madison, WI) with SP6
promoter to ensure robust expression in Xenopus oocytes.
RNA Transcription and Expression in Xenopus Oocytes
The Na v 1.5 cRNA was synthesized from an EcoR I linearized DNA template and was transcribed in vitro using SP6 RNA-polymerase and the mMESSAGE mMACHINE Xenopus oocytes that expressed Na v 1.5 were clamped at −100 mV before electrophysiological recordings. Robust Na + currents were induced in oocytes when depolarized by a series of step stimuli ranging from −100 mV to +70 mV.
To minimize individual difference between samples, only oocytes with peak I Na currents elicited at −20 mV or −30 mV were chosen for subsequent tests [18, 19] .
Electrophysiological Recording
Two-electrode voltage-clamp recordings were performed using an Axon 900A amplifier (Molecular Devices, 
Data Analysis
Mean conductance (G) was calculated using the equation The voltage-dependence of fast inactivation and slow inactivation was described by the two-state Boltzmann 
RESULTS
Voltage-and Use-dependent Blockade by Bupivacaine
Although it has been reported that blockade of the Na + channel by LAs is differentially modulated by β1 and β3 subunits [20] , this was not of concern in the present study in that we intended to provide a direct assessment of the pharmacological effects of bupivacaine on the Na v 1.5 channel. Hence, Xenopus oocytes were chosen as an expression system of Na v 1.5 alone.
Robust Na + currents of Na v 1.5 were elicited by step stimuli from a holding potential of −100 mV to +70 mV with 100 ms duration (Fig. 1A) . To reach equilibrium for each recording, oocytes were perfused with the external solution of ND96 for 10 min prior to the subsequent protocols.
After application of 50 μmol/L bupivacaine for 10 min, the peak Na v 1.5 current was inhibited by ~70%. The I-V curves showed that the blockade of I Na occurred at quite depolarized potentials (about −40 mV for 10-100 μmol/L) ( μmol/L had little effect on I Na , the remaining currents being 90.58 ± 1.06% of control (P >0.05, n = 6). The I Na reduction rates induced by bupivacaine were 56.31 ± 3.60% at 10 μmol/L (P <0.001, n = 6); 69.24 ± 2.08% at 50 μmol/L (P <0.001, n = 5); and 72.37 ± 3.24% at 100 μmol/L (P <0.001, n = 5) (Fig. 1C) . Accordingly, the dose-response relationship fit the Hill equation well, giving an IC 50 of 4.51 μmol/L with a Hill coeffi cient of 1.33 (Fig. 1C, inset) .
Since the hallmark of most class I LAs is the induction of a use-dependent blockade of Na + channels, the kinetic properties of bupivacaine blockade was characterized in Na v 1.5 with steps of depolarizing stimuli from −100 mV to +10 mV at 0.5, 1, and 2 Hz for 60 pulses each. Each peak Na + current was normalized to the peak current during the fi rst pulse. Under control conditions, there was hardly any reduction in peak I Na (Fig. 2 ). After treatment with bupivacaine at different concentrations, the potency of blockade was progressively enhanced. Notably, the blockade by bupivacaine at 1 μmol/L tested at 2 Hz was more efficient than that tested at 1 Hz, while this relationship was reversed at higher concentrations (50 and 100 μmol/L) (P <0.001, n = 5-6, Fig. 2C ). The development of blockade was accelerated with increasing bupivacaine concentration at all frequencies tested (Fig. 2B, D) . Almost all the use-dependent blockade at different concentrations was achieved within the fi rst 15 pulses, indicating a "fastin" (in that the inhibition rate was fast) manner. When fitted to the first order exponential equation, the resultant time constants for entry into the steady-state blockade decreased in a nonlinear frequency-dependent manner, prominently for 0.5 and 2 Hz but less effi ciently for 1 Hz (Fig.   2D ).
Bupivacaine Shifts the Voltage-dependent Relationship of Activation and Inactivation
To give a full assessment of the pharmacological profile of bupivacaine, the voltage-dependent activation and steady-state inactivation of expressed Na v 1.5 channels were tested. Since 200 μmol/L bupivacaine significantly depressed the channel activity, amplitudes recorded at this concentration did not refl ect its real pharmacological effect.
Among the four concentrations tested (except 1 μmol/L), the voltage-dependent activation curves were substantially shifted to more depolarized potentials in a dose-dependent manner (7.71 mV for 10 μmol/L, 9.21 mV for 50 μmol/L, and 12.01 mV for 100 μmol/L) (Fig. 3B , Table 1 ).
Compared with the voltage-dependent activation, the steady-state inactivation was less sensitive to bupivacaine. All the inactivation curves were shifted to more hyperpolarized potentials, except for the 10 μmol/L bupivacaine treatment (Fig. 3B ). Bupivacaine at 50 μmol/L hyperpolarized the steady-state inactivation curve by 8.25
mV (P <0.001, n = 6), about double that of 1 μmol/L (3.47 mV; P <0.001, n = 6) and 100 μmol/L (4.31 mV; P <0.001, n = 6). In contrast, 10 μmol/L bupivacaine slightly depolarized the steady-state inactivation by 1.26 mV (P <0.01, n = 6) ( Table 1) . Bupivacaine also significantly altered the slope factor of the inactivation curves at all concentrations except 1 μmol/L (Table 1) .
B u p i v a c a i n e M o d i f i e s t h e G a t i n g K i n e t i c s o f Inactivation
Since LAs have a higher affinity for channels in the inactivated state, we considered that the blockade of I Na by bupivacaine may be due to changes in the fast and slow inactivation components of Na v 1.5. To test this hypothesis, the voltage-dependent relationships of these two components were explored.
The voltage-dependence of fast and slow inactivation was investigated using protocols with prepulses from −100 mV to +60 mV for different durations (10 ms for fast and 2 000 ms for slow inactivation) (Fig. S1A, B, inset) .
Overall, the slow inactivation was more vulnerable to modulation by bupivacaine, with V 1/2 shifted to a more hyperpolarized potential than that of fast inactivation at all tested concentrations (1, 10, 50, and 100 μmol/L). In slow inactivation, 50 μmol/L bupivacaine induced the most pronounced hyperpolarization shift (20.22 mV) (P <0.001, n = 6) and modest shifts at 10 and 20 μmol/L (3.14 and 11.98 mV respectively; both P <0.001, n = 6), Bupivacaine at 1 μmol/L barely caused any shift in the slow inactivation curve (P >0.05, n = 6). Finally, the fraction of channels resistant to slow inactivation was decreased by bupivacaine in a dose-dependent manner (Fig. S2 ).
The effect of bupivacaine on the fast inactivation of Na v 1.5 was not as prominent as that on slow inactivation.
At 100 μmol/L, bupivacaine even markedly depolarized Table 1 . Sample sizes of each group are shown in Table 1 . C: Normalized current-voltage (I-V) relationship of Na v 1.5 before and after bupivacaine adiministration. Mean ± SEMs. 
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induced by 10 μmol/L bupivacaine was evident, which was increased by 3.8% at −20 mV (P <0.05, n = 5), 4.1% at −10 mV (P <0.05, n = 4), and 5.2% at 0 mV (P <0.05, n = 3) (Fig. 4B) . In addition, this increase was also found at −20 mV (3.9%, P <0.05, n = 5) for 50 μmol/L, and at −10 mV (3.8%, P <0.05, n = 6) for 1 μmol/L (Fig. 4B) . Notably, a small but notable decrease for 100 μmol/L at −30 mV (9.0%, P <0.05, n = 4) was seen, which may have been caused by the disrupted gating property of channels at high concentrations of bupivacaine.
Bupivacaine Modulates the Development of Slow
Inactivation and the Recovery from Inactivation
Since slow inactivation is an important factor governing Na v 1.5 availability in the activated state, we then determined whether bupivacaine affects the entry into slow inactivation (Fig. 5) . Prepulses to −10 mV and −80 mV of variable durations were used to monitor the inactivation onset of Na v 1.5 in the open (Fig. 5A ) and closed states (Fig.   5B ). By fi tting the decay currents to the double-exponential equitation, we compared the time constants for the development of slow inactivation at different concentrations of bupivacaine (Fig. 5, right panels) . At −10 mV, bupivacaine at all concentrations accelerated both phase I (t 1 ) and phase II (t 2 ) of the decay in a dose-dependent manner (Table 3 ). But at −80 mV, bupivacaine at all concentrations delayed phase I, and the time constants of phase II were delayed at 20 and 50 μmol/L (Table 3 ). These results suggest that bupivacaine is capable of accelerating the development of open-state slow inactivation of Na v 1.5
but not that of closed-state slow inactivation.
The acceleration of entry into slow inactivation may be one of the reasons for the voltage-dependent block of Na v 1.5 currents by bupivacaine. However, the high-affi nity binding of bupivacaine to the inactivated Na + channel might also affect the recovery time from inactivation, which would reduce the number of channels available to reopen, as seen in the actions of lidocaine [21] . Therefore, the recovery time and rate of kinetics were examined for Na v 1.5 at different concentrations of bupivacaine.
Recovery from inactivation was determined using a two-pulse protocol consisting of a 50-ms conditioning 708 prepulse at 0 mV followed by a varied recovery time (0-100 ms) at −120 mV, after which a test pulse to −10 mV for 50 ms was applied (Fig. 6A, inset) . 
DISCUSSION
Regarded as the most long-acting and effi cient LA widely used in clinical management, bupivacaine is still associated with severe cardiac and CNS toxicity, which restricts its use as a safe and controllable LA [22] . The major mechanism for bupivacaine depression of cardiac conduction is considered to be the fast block of Na + channels during action potential transmission, which results in slow recovery from block during diastole [23] . Recently, levobupivacaine, a single enantiomer of bupivacaine, has been introduced as a new long-acting LA with potentially reduced toxicity compared with bupivacaine [24] . Even so, bupivacaine has not been replaced in the market, probably due to the lack of perceived safety benefits and/or the consideration of additional costs for the switch to levobupivacaine, which is ~57% more expensive than bupivacaine [22] . Therefore, a
safer strategy for the current use of bupivacaine is urgently needed. To achieve this, an in-depth investigation of how bupivacaine interacts with Na + channels and the underlying mechanisms need to be illuminated.
In the present study, we examined the pharmacological profi le of bupivacaine on Na v 1.5, with particular interest in how it interacts with channels expressed in backgroundfree Xenopus oocytes.
It is well-established that bupivacaine has a higher affi nity for inactivated Na + channels [21] . [25] . The latter type of inactivation only occurs at very high concentrations and is therefore considered to be a low-affi nity block, so this was not a concern in the current residues within S6, such as L1280 and P1759 [10] . Here, we found that between the fast and slow inactivation, bupivacaine preferably acted on the latter, for which the voltage-dependency and time constants were substantially changed. This finding is in agreement with the fact that the slow inactivation is thought to be accompanied by rearrangement of the channel pore in DIV [26] . use of the S(-)-enantiomer to reduce cardiac toxicity [11] .
However, as pure S(-)-enantiomer is far more expensive and bupivacaine is clinically used as a racemic mixture, this study provides clues, at least in part, for a safer strategy of the current use of bupivacaine.
In summary, our results revealed that the voltagedependent block of Na v 1.5 by bupivacaine arises not only from a depolarized shift in voltage-dependent activation but also from hyperpolarized inactivation. In particular, bupivacaine has a preference for the open-state inactivated channels, the binding sites of which may rely on the hydrophobic residues within DIII-S6 and DIV-S6. In addition, overdose of bupivacaine could cause a drastic decrease in channel activity that may partially contribute to the clinical cardiac or CNS toxicity.
